论文部分内容阅读
目的:探讨干扰素α-1b联合病毒唑治疗丙型病毒性肝炎的临床疗效和安全性。方法:67例丙型病毒性肝炎患者被随机分为联合治疗组(干扰素α-1b加病毒唑,32例)与对照组(单用干扰素α-1b,35例)。分别观察两组治疗前后临床症状体征的改善情况、生化应答率、病毒应答率和毒副作用。结果:治疗结束时联合治疗组临床症状体征的缓解率为96.88%,生化应答率为96.88%,病毒应答率为68.75%;对照组上述指标分别为80%、80%、48.57%.经检验无显著性差异(P>0.05)。但随访1年联合治疗组的持续应答率为43.75%,而对照组的持续应答率为14.29%,差异显著(P<0.01)。联合治疗组副作用除贫血较对照组明显外,其他与对照组相仿。结论:干扰素α-1b和病毒唑联合治疗可以增强远期抗病毒疗效且耐受性好,可成为治疗丙型肝炎的主要疗法之一。
Objective: To investigate the clinical efficacy and safety of interferon α-1b combined with ribavirin in the treatment of hepatitis C virus. Methods: Sixty-seven patients with viral hepatitis C were randomly divided into combined treatment group (interferon α-1b plus ribavirin, 32 cases) and control group (interferon α-1b alone, 35 cases). The improvement of clinical symptoms and signs, biochemical response rate, virus response rate and toxic and side effects were observed before and after treatment. Results: The remission rate of clinical symptoms and signs was 96.88%, the rate of biochemical response was 96.88% and the rate of virus response was 68.75% at the end of treatment. The above indexes in the control group were 80%, 80% and 48.57% respectively. Significant difference (P> 0.05). However, the one-year follow-up of the combination therapy group continued response rate was 43.75%, while the control group continued response rate was 14.29%, the difference was significant (P <0.01). In addition to the side effects of combination therapy group was significantly anemic compared with the control group, the other similar to the control group. Conclusion: The combined treatment of interferon α-1b and ribavirin can enhance long-term anti-viral efficacy and well tolerated, and can be one of the main therapies for the treatment of hepatitis C.